Grail (GRAL) Stock Price, News & Analysis

Company Overview

GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.

Key Stats

• Today's Range: $22.74 to $24.92
• 50-Day Range: $12.93 to $23.62
• 52-Week Range: $12.33 to $24.92
• Volume: 891,755 shs
• Average Volume: 1.06 million shs
• Market Capitalization: $793.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.00
• Consensus Rating: Hold

Grail Stock Analysis - MarketRank™

Grail scored higher than 11% of companies evaluated by MarketBeat, and ranked 927th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Grail has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Grail has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Grail are expected to grow in the coming year, from ($65.16) to ($15.15) per share.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.41% of the float of Grail has been sold short.

Short Interest Ratio / Days to Cover

Grail has a short interest ratio ("days to cover") of 6.

Change versus previous month

Short interest in Grail has recently increased by 15.87%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Grail does not currently pay a dividend.

Dividend Growth

Grail does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

15.41% of the float of Grail has been sold short.

Short Interest Ratio / Days to Cover

Grail has a short interest ratio ("days to cover") of 6.

Change versus previous month

Short interest in Grail has recently increased by 15.87%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.38

News Sentiment

Grail has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Grail this week, compared to 5 articles on an average week.

Search Interest

7 people have searched for GRAL on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.

MarketBeat Follows

14 people have added Grail to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Grail insiders have sold 184.93% more of their company's stock than they have bought. Specifically, they have bought $757,298.00 in company stock and sold $2,157,762.00 in company stock.

GRAL Stock Analysis - Frequently Asked Questions

How have GRAL shares performed this year?

Grail's stock was trading at $14.57 at the start of the year. Since then, GRAL shares have increased by 62.1% and is now trading at $23.62.
View the best growth stocks for 2024 here.

How do I buy shares of Grail?

Shares of GRAL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Grail own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Grail investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V).

Company Calendar

• Today: 12/18/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical laboratories
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:GRAL
• Previous Symbol: NASDAQ:GRAL
• CUSIP: N/A
• CIK: 1699031
• Web: N/A
• Phone: (650) 771-9796
• Fax: N/A
• Employees: 1,360
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $16.00
• High Stock Price Target: $16.00
• Low Stock Price Target: $16.00
• Potential Upside/Downside: -32.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.65
• Quick Ratio: 9.65

Sales & Book Value

• Annual Sales: $117.67 million
• Price / Sales: 6.74
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 33,601,000
• Free Float: N/A
• Market Cap: $793.66 million
• Optionable: Optionable
• Beta: N/A